Title : Efficacy and Safety of Docetaxel and Sodium Cantharidinate Combination vs. Either Agent Alone as Second-Line Treatment for Advanced/Metastatic NSCLC With Wild-Type or Unknown EGFR Status: An Open-Label, Randomized Controlled, Prospective, Multi-Center Phase III Trial (Cando-L1).

Pub. Date : 2021

PMID : 34976813






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Also, SCA plus DOX can significantly improve OS and exerted a significant synergistic effect, with good safety and tolerance profile. Docetaxel Moloney sarcoma oncogene Mus musculus